Effects of 17β-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 4, 1999, Pages 587-598

  Chen, Yi Jen ^b   Lee, Shih Huang ^b   Hsieh, Ming Hsiung ^b   Hsiao, Chien Ju ^b   Yu, Wen Chung ^b   Chiou, Chuen Wang ^b   Chen, Shih Ann ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Atrial fibrillation; Cisapride; Estrogen; Long QT syndrome; Torsades de pointes

Indexed keywords

ESTRADIOL; ANTIARRHYTHMIC AGENT; CISAPRIDE; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; DISEASE PREDISPOSITION; DOG; ESTRADIOL BLOOD LEVEL; FEMALE; HEART DEPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HORMONAL REGULATION; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TORSADE DES POINTES; ACTION POTENTIAL; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART ATRIUM; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CISAPRIDE; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ESTRADIOL; FEMALE; HEART ATRIA; HEART CONDUCTION SYSTEM; HEART RATE; SEX CHARACTERISTICS; TORSADES DE POINTES; VERAPAMIL;

EID: 0033113189     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00716.x     Document Type: Article

References (34)

1. 1. Feinberg WM, Blackshear JL, Laupacis A, et al: Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155:469-473.
2. 2. Benjamin EJ, Levy D, Vaziri SM, et al: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271:840-844.
3. 3. Benjamin EJ, Wolf P, Kannel W. The epidemiology of atrial fibrillation. In Falk R, Podrid P, eds: Atrial Fibrillation Mechanism and Management. Lippincott-Raven Publisher, Philadelphia, 1997, pp. 1-22.
4. 4. Lehmann MH, Hardy S, Archibald D, et al: Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996:94:2535-2541.
5. 5. Makkar R, Fromm BS, Steinman RT, et al: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993:270:2590-2597.
6. 6. Ahmad SR, Wolfe SM: Cisapride and torsades de pointes. Lancet 1995;345-358.
7. 7. Bran S, Murray WA, Hirsch AV, et al: Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-768.
8. 8. Wysowski DK, Bacsanyi J: Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-291.
9. 9. Lee SH, Chen SA, Yu WC, et al: Regional difference of recovery of atrial refractory period after chronic atrial pacing. Circulation 1999 (in press).
10. 10. Jose AD, Taylor RR: Autonomic blockade by propranolol and atropine to study intrinsic myocardial function in man. J Clin Invest 1989;48:2019-2031.
11. 11. Samaan SA, Crawford MH: Estrogen and cardiovascular function after menopause. J Am Coll Cardiol 1995; 26:1403-1410.
12. 12. Levine JH, Spear JF, Guarnieri T, et al: Cesium chloride-induced long QT syndrome: Demonstration of afterdepolarization and triggered activity in vivo. Circulation 1985;72:1092-1103.
13. 13. Damiano BP, Rosen MR: Effect of pacing on triggered activity induced by early afterdepolarizations. Circulation 1984;69:1013-1025.
14. 14. Dessertenne F: La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur Vaiss 1966;59: 263-272.
15. 15. Edqvist LE, Johansson ED, Kasstrom H, et al: Blood plasma levels of progesterone and oestradiol in the dog during the oestrous cycle and pregnancy. Acta Endocrinol 1975;78:554-564.
16. 16. Tanno K, Benditt DG, Sakaguchi S: The effect of 17 β-estradiol on delayed outward potassium current. (Abstract) Circulation 1996;94:1-529.
17. 17. Goette A, Honeycutt C, Langberg JJ: Electrical remodeling in atrial fibrillation: Time course and mechanisms. Circulation 1996;94:2968-2974.
18. 18. Daoud EG, Bogun F, Goyal R, et al: Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996;94:1600-1606.
19. 19. Daoud EG, Knight BP, Weiss R, et al: Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997;96: 1542-1550.
20. 20. Yu WC, Chen SA, Lee SH, et al: Tachycardia-induced change of atrial refractory period in humans: Rate dependency and effects of antiarrhythmic drugs. Circulation 1998;97:2331-2337.
21. + in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992;106:739-745.
22. 22. Puisieux FL, Adamantidis MM, Dumotier BM, et al: Cisapride-induced prolongation of cardiac action potential and early afterdepolarization in rabbit Purkinje fibres. Br J Pharmacol 1996;117:1377-1379.
23. 23. Carlsson L, Amos GJ, Anderson B, et al: Electrophysiologic characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential? J Pharmacol Exp Ther 1997;282:220-227.
24. 24. Hohnloser SH, Singh BN: Proarrhythmia with class III antiarrhythmic drugs: Definition, electrophysiologic mechanism, incidence, predisposing factors and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-936.
25. 25. Surawicz B: Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarization? J Am Coll Cardiol 1989;14:172-184.
26. 26. Habbab MA, El-Sherif N: Drug-induced torsades de pointes: Role of early afterdepolarizations and dispersion of repolarization. Am J Med 1990;89:241-246.
27. 27. Hii JT, Wyse DG, Gillis AM, et al: Precordial QT interval dispersion as a marker of torsade de pointes: Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-1382.
28. 28. Priori SG, Napolitano C, Diehl L, et al: Dispersion of the QT interval: A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994;89: 1681-1689.
29. 29. Verduyn SC, Vos MA, ven der Zande J, et al: Role of interventricular dispersion of repolarization in acquired torsade de pointes: Reversal by magnesium. Cardiovasc Res 1997; 34:453-463.
30. 30. Demolis JL, Funck-Brentano C, Ropers J, et al: Influence of dofetilide on QT interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996;94:1592-1599.
31. 31. Rautaharju PM, Zhou SH, Wong S, et al: Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8:690-695.
32. 32. Drici MD, Burklow TR, Haridasse V, et al: Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-1474.
33. 33. McCallum RW, Prakash C, Campoli-Richard DM, et al: Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988;36:652-681.
34. th Edition. McGraw-Hill, New York, 1996, pp. 1411-1440.